iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases

Registry record from ClinicalTrials.gov (NCT03549754). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 35000 participants (ESTIMATED). Conditions: Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure. Primary outcome measures: 1. Age of particpants , At Baseline; 2. Percentage of Participants by Sex , At baseline; 3. Percentage of Participants by Ethnicity , At Baseline; 4. Percentage of Participants by Education Level , At Baseline; 5. Percentage of Participants by Marital Status , At Baseline; 6. Percentage of Participants with Family History of Cardiovascular and Renal-Metabolic Disease , At Baseline; 7.Percentage of Participants by Physical Activity Level , At Baseline; 8. Percentage of Participants by Smoking Status , At Baseline; 9. Percentage of Participants by Alcohol Consumption , At Baseline; 10. Body Weight of Participants , At Baseline; 11. Height of Participants , At Baseline; 12. Body Mass Index (BMI) of Participants , At Baseline; 13. Waist Circumference of Participants , At Baseline; 14. Waist-to-Hip Ratio of Participants , At Baseline; 15. Waist-to-Height Ratio of Participants , At Baseline; 16. Percentage of Participants by Cardiac and Renal Functional Measurements Category , At Baseline; 17. Primary Disease Duration , At Baseline; 18. Percentage of Participants by Number and Types of Comorbidities , At Baseline; 19. Percentage of Participants by NYHA Functional Class , At Baseline; 20. Percentage of Participants by Heart Failure Phenotype , At Baseline; 21. Percentage of Participants by Heart Failure Etiology , At Baseline; 22. Percentage of Participants by CKD Etiology , At Baseline; 23. Percentage of Participants by Hypertension Stage , At Baseline; 24. Percentage of Participants by Secondary Hypertension Etiology , At Baseline; 25. Office Systolic and Diastolic Blood Pressure , At Baseline; 26. Home Blood Pressure Monitoring (HBPM) Systolic and Diastolic Values , At Baseline; 27. Ambulatory Blood Pressure Monitoring (ABPM) Systolic and Diastolic Values , At Baseline; 28. Blood HbA1c , Average of 3 years; 29. Fasting Glucose , Average of 3 years; 30. Lipid Profile Testing , Average of 3 years; 31. Serum Creatinine , Average of 3 years; 32. Estimated Glomerular Filtration Rate (eGFR) , Average of 3 years; 33. Urine Albumin-to-Creatinine Ratio (UACR) , Average of 3 years; 34. Serum Electrolyte Values , Avergae of 3 years; 35. Frequency of HbA1c Testing , Average of 3 years; 36. Frequency of Fasting Glucose Testing , Average of 3 years; 37. Frequency of Lipid Profile Testing , Average of 3 years; 38. Frequency of Serum Creatinine Testing , Average of 3 years; 39. Frequency of eGFR Assessment , Average of 3 years; 40. Frequency of Urine Albumin-to-Creatinine Ratio Testing , Average of 3 years; 41. Echocardiography , Average of 3 years; 42. Electrocardiogram (ECG) , Average of 3 years; 43. Participants Receiving Dietary Modification Counseling , Average of 3 years; 44. Participants Enrolled in Exercise Programs , Average of 3 years; 45. Participants Receiving Weight Management Interventions , Average of 3 years; 46. Participants Receiving Smoking Cessation Counseling , Average of 3 years; 47. Participants Receiving Alcohol Reduction Counseling , Average of 3 years; 48. Percentage of Participants by Line of Treatment , Average of 3 years; 49. Percentage of Participants by Drug Class , Average of 3 years; 50. Percentage of Participants Undergoing Cardiac Surgeries (CABG or PCI) , Average of 3 years; 51. Percentage of Participants Receiving Dialysis , Average of 3 years; 52. Percentage of Participants with Cardiac Device Implantation , Average of 3 years; 53. Mean Duration of Pharmacological Treatments , Average of 3 years; 54. Drug Dose of Pharmacological Treatments , Average of 3 years; 55. Number of Primary Care Visits per Participant , Average of 3 years; 56. Number of Tertiary Care Hospital Visits per Participant , Average of 3 years; 57. Number of Specialist Care Visits per Participant , Average of 3 years; 58.Number of Emergency Department Visits per Participant , Average of 3 years; 59. All-Cause Hospitalizations , Average of 3 years; 60. Disease-Specific Hospitalizations , Average of 3 years; 61. All-Cause Emergency Department Visits , Average of 3 years; 62. Disease-Specific Emergency Department Visits , Average of 3 years; 63. Length of Hospital Stay , Average of 3 years. Brief summary: To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases